{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hartrampf PE"],"funding":["Universitätsklinikum Würzburg","Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg"],"pagination":["4262-4270"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9525362"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["49(12)"],"pubmed_abstract":["<h4>Background</h4>Radioligand therapy (RLT) with <sup>177</sup>Lu-labeled prostate-specific membrane antigen (PSMA) ligands is associated with prolonged overall survival (OS) in patients with advanced, metastatic castration-resistant prostate cancer (mCRPC). A substantial number of patients, however, are prone to treatment failure. We aimed to determine clinical baseline characteristics to predict OS in patients receiving [<sup>177</sup>Lu]Lu-PSMA I&T RLT in a long-term follow-up.<h4>Materials and methods</h4>Ninety-two mCRPC patients treated with [<sup>177</sup>Lu]Lu-PSMA I&T with a follow-up of at least 18 months were retrospectively identified. Multivariable Cox regression analyses were performed for various baseline characteristics, including laboratory values, Gleason score, age, pri"],"journal":["European journal of nuclear medicine and molecular imaging"],"pubmed_title":["Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [<sup>177</sup>Lu]Lu-PSMA I&T during long-term follow-up."],"pmcid":["PMC9525362"],"funding_grant_id":["Z-02/85"],"pubmed_authors":["Seitz AK","Kubler H","Weinzierl FX","Schirbel A","Rowe SP","Buck AK","Serfling SE","Hartrampf PE","Werner RA"],"additional_accession":[]},"is_claimable":false,"name":"Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [<sup>177</sup>Lu]Lu-PSMA I&T during long-term follow-up.","description":"<h4>Background</h4>Radioligand therapy (RLT) with <sup>177</sup>Lu-labeled prostate-specific membrane antigen (PSMA) ligands is associated with prolonged overall survival (OS) in patients with advanced, metastatic castration-resistant prostate cancer (mCRPC). A substantial number of patients, however, are prone to treatment failure. We aimed to determine clinical baseline characteristics to predict OS in patients receiving [<sup>177</sup>Lu]Lu-PSMA I&T RLT in a long-term follow-up.<h4>Materials and methods</h4>Ninety-two mCRPC patients treated with [<sup>177</sup>Lu]Lu-PSMA I&T with a follow-up of at least 18 months were retrospectively identified. Multivariable Cox regression analyses were performed for various baseline characteristics, including laboratory values, Gleason score, age, pri","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-22T09:38:58.06Z","creation":"2024-11-15T00:42:20.898Z"},"accession":"S-EPMC9525362","cross_references":{"pubmed":["35650263"],"doi":["10.1007/s00259-022-05853-2"]}}